Vaped Phenanthrene

NCT07134426 — Not applicable, Recruiting, 100 participants, University of Minnesota

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Investigating Vaped Phenanthrene Biomarkers in Former Smokers

Registry	NCT07134426
Status	Recruiting
Phase	Not applicable
Study type	Interventional; na, single group, masking: none, basic science
Enrollment	100 (Estimated)
Sponsor	University of Minnesota (Other)
Conditions	Former Smoker, Non-Smoker
Interventions	D10-phenanthrene (Other)
Dates	start 2026-09-01, primary completion 2027-09-01 (estimated), completion 2028-06-30 (estimated), first posted 2025-08-21, last updated 2026-09-03
Locations	1 site in United States

-Summary

Some people who used to smoke cigarettes continue to be at higher risk of developing lung cancer, even years after quitting. This study will look to see if a specific chemical, phenanthrene, is broken down in the lungs of former smokers through more harmful pathways than never-smokers. If former smokers break down chemicals that enter their lungs through more harmful pathways this might be putting them at higher risk for developing lung cancer even though they quit smoking. This information may help find better ways to prevent or treat cancer in the future.

This study is under an IND, but the drug is not being studied; instead, it is being used as a marker for drug metabolism.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
D10-phenanthrene	Other	Other: D10-phenanthrene	All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

D10-phenanthrene (Other): All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].

+Outcome measures

Primary outcomes

Urinary Ratio of D10PheT/D9PhOH [24 hours after vaping phenanthrene]: The ratio of D10-phenanthrene tetraol to D9-phenanthrene phenols in the urine will determine how the lung breaks down a class of cancer-causing chemicals called Polycyclic Aromatic Hydrocarbons (PAHs). The higher this ratio the more the lungs break down these chemicals through harmful pathways, which might increase cancer risk. The lower the ratio the more the lung breaks down the chemicals through safer pathways.
TNE [Baseline measure]: Total nicotine equivalents will be measured in the urine samples to confirm that study participants are not using tobacco or nicotine products.

+Eligibility

Sex: All, ages: 21 Years to any, accepts healthy volunteers

Inclusion Criteria:

* > 21 years of age
* In good physical \& mental health
* In stable physical \& mental health
* Have tried vaping
* Former daily cigarette smokers who quit 1-20 year ago
* Non-smokers who have not used tobacco or nicotine products

Exclusion Criteria:

* Has any respiratory disease (ex - asthma, COPD, etc...)
* Has/had high blood pressure
* Has/had liver disease
* Has/had cancer
* Has experience negative effects when vaped previously
* Pregnant or nursing

+Locations (1)

Facility	City	Country	Status
University of Minnesota	Minneapolis, Minnesota	United States	Recruiting

+Investigators

Stephen Hecht, Principal investigator, University of Minnesota